ES2059729T5 - Preparado farmaceutico de liberacion controlada y metodo para producir el mismo. - Google Patents

Preparado farmaceutico de liberacion controlada y metodo para producir el mismo.

Info

Publication number
ES2059729T5
ES2059729T5 ES89302767T ES89302767T ES2059729T5 ES 2059729 T5 ES2059729 T5 ES 2059729T5 ES 89302767 T ES89302767 T ES 89302767T ES 89302767 T ES89302767 T ES 89302767T ES 2059729 T5 ES2059729 T5 ES 2059729T5
Authority
ES
Spain
Prior art keywords
pharmaceutical preparation
produce
same
substance
controlled liberation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89302767T
Other languages
English (en)
Other versions
ES2059729T3 (es
Inventor
Masayoshi Samejima
Kazuo Noda
Yoshiyuki Hirakawa
Hiroyuki Yoshino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13722933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2059729(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of ES2059729T3 publication Critical patent/ES2059729T3/es
Application granted granted Critical
Publication of ES2059729T5 publication Critical patent/ES2059729T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE EXPLICA UNA PREPARACION FARMACEUTICA DE LIBERACION SOSTENIDA, QUE COMPRENDE UN NUCLEO QUE CONTIENE EL PRINCIPIO ACTIVO FARMACEUTICO, Y UNA PELICULA POROSA DE UNA SUSTANCIA POLIMERICA HIDROFOBICA O UNA SUSTANCIA POLIMERICA HIDROBFOBICA Y UNA SUSTANCIA POLIMERICA HIDROFILICA, EL NUCLEO SE RECUBRE CON LA MEMBRANA POROSA. TAMBIEN SE EXPLICA EL METODO PARA SU OBTENCION.
ES89302767T 1988-03-31 1989-03-21 Preparado farmaceutico de liberacion controlada y metodo para producir el mismo. Expired - Lifetime ES2059729T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8060488 1988-03-31

Publications (2)

Publication Number Publication Date
ES2059729T3 ES2059729T3 (es) 1994-11-16
ES2059729T5 true ES2059729T5 (es) 2002-09-16

Family

ID=13722933

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89302767T Expired - Lifetime ES2059729T5 (es) 1988-03-31 1989-03-21 Preparado farmaceutico de liberacion controlada y metodo para producir el mismo.

Country Status (21)

Country Link
US (1) US5068112A (es)
EP (1) EP0335560B2 (es)
KR (1) KR950007202B1 (es)
AT (1) ATE91888T1 (es)
AU (1) AU610711B2 (es)
BG (1) BG50712A3 (es)
CA (1) CA1339078C (es)
DE (1) DE68907762T3 (es)
DK (1) DK156289A (es)
ES (1) ES2059729T5 (es)
FI (1) FI101344B1 (es)
FR (1) FR2629344B1 (es)
HK (1) HK76195A (es)
HU (1) HU201882B (es)
IE (1) IE64348B1 (es)
IL (1) IL89695A0 (es)
NO (1) NO178136C (es)
PH (1) PH25791A (es)
PT (1) PT90153B (es)
RU (1) RU1836083C (es)
ZA (1) ZA892131B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101344B1 (fi) † 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US6350462B1 (en) * 1990-12-26 2002-02-26 Olympus Optical Co., Ltd. Hollow porous ceramic carrier for embedding in patient for sustained medicament release and method of preparation thereof
JP2538134B2 (ja) * 1991-04-08 1996-09-25 田辺製薬株式会社 徐放性製剤およびその製造法
WO1992020326A1 (en) * 1991-05-20 1992-11-26 Marion Laboratories, Inc. Multi-layered controlled release formulation
EP0520119A1 (de) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US5536505A (en) * 1993-12-15 1996-07-16 Eastman Chemical Company Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
US5523095A (en) * 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
ES2120354B1 (es) * 1996-02-12 1999-07-01 Univ Sevilla Dispositivo terapeutico para direccionar farmacos hacia el tramo del tracto gastrointestinal deseado en funcion de las caracteristicas fisicoquimicas del mismo.
DE19628776A1 (de) * 1996-07-17 1998-01-22 Bayer Ag Oral applizierbare Granulate von Hexahydropyrazinderivaten
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
BR9802915A (pt) * 1997-09-12 2000-01-11 Oscar Gold Procedimento para formar composições farmaceuticas em pilulas ou granulos substancialmente esfericos, de ação controlada e continuada, contendo como agente ativo o (7-bromo-1,3-diidro-5-(2-piridninilo)-2h-1,4-benzodiazep ina-2(1h)-um)
PT1030839E (pt) 1997-11-10 2004-05-31 Searle & Co Utilizacao de iminoacucares para tratar a resistencia a multifarmacos
DE69932154T2 (de) 1998-02-12 2007-05-31 G.D. Searle Llc, Chicago Verwendung von n-substituirten-1,5-dideoxy-1,5-imino-d-glucitolen zur behandlung von hepatitis infektionen
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
JP4533531B2 (ja) 1998-04-03 2010-09-01 ビーエム リサーチ エイ／エス 制御放出組成物
ATE402701T1 (de) * 1999-02-12 2008-08-15 United Therapeutics Corp N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino- - glucitol zur behandlung von hepatitis-virus- infektionen
JP2003505501A (ja) 1999-02-12 2003-02-12 ジー・ディー・サール・アンド・カンパニー 肝炎ウィルス感染の処置のためのグルカミン化合物
SE9903879D0 (sv) * 1999-10-28 1999-10-28 Ethical Pharmaceuticals Sweden Multipor food protection
JP2003518487A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク ヒドロゲル駆動型積層薬物製剤
KR100574213B1 (ko) 2000-01-27 2006-04-27 다나베 세이야꾸 가부시키가이샤 서방성 제제 및 그의 제조 방법
JP2003522791A (ja) * 2000-02-14 2003-07-29 ファルマシア コーポレイション 肝炎ウイルス感染症治療用ｎ‐置換‐１，５‐ジデオキシ‐１，５‐イミノ‐ｄ‐グルシトール化合物の使用
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US20040208936A1 (en) * 2002-07-22 2004-10-21 Roland Chorin Novel compositions
EP1562552A1 (en) 2002-11-08 2005-08-17 Egalet A/S Controlled release carvedilol compositions
EP1607092A4 (en) * 2003-03-17 2010-12-15 Takeda Pharmaceutical COMPOSITIONS WITH CONTROLLED RELEASE
ATE454886T1 (de) 2003-03-26 2010-01-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
US7115283B2 (en) * 2003-05-06 2006-10-03 Access Business Group International Llc Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals
ES2272914T3 (es) * 2003-05-20 2007-05-01 Ethypharm Composicion farmaceutica oral de liberacion sostenida.
FR2855412B1 (fr) * 2003-05-27 2007-05-25 Menvielle Bourg Fabienn Joanny Composition a liberation prolongee de magnesium, et son application dans le domaine therapeutique, cosmetique et nutritionnel
WO2004112746A1 (en) * 2003-06-26 2004-12-29 Korea Research Institute Of Chemical Technology Controlled release-drug delivery system for oral administration
JPWO2005011637A1 (ja) * 2003-08-04 2006-09-14 エーザイ株式会社 用時分散型製剤
KR100615952B1 (ko) 2004-05-27 2006-08-28 한국화학연구원 서방형 약물 전달 시스템
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
EP1880718B1 (de) * 2006-07-10 2011-09-21 Dr. R. Pfleger Chemische Fabrik GmbH Pharmazeutische Zubereitung für die orale Verabreichung mit gesteuerter Wirkstofffreisetzung im Dünndarm und Verfahren zu ihrer Herstellung
NZ577560A (en) * 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
WO2008112388A1 (en) 2007-03-14 2008-09-18 Drugtech Corporation Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
AU2008286914B2 (en) 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
FR2931361B1 (fr) * 2008-05-20 2012-08-31 Menvielle Bourg Fabienne Joanny Systeme a base de magnesium et son utilisation en cosmetique
FR2931359B1 (fr) * 2008-05-20 2012-12-21 Menvielle Bourg Fabienne Joanny Utilisation d'une matrice pour administration orale de magnesium a liberation prolongee, et composition contenant cette matrice
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
PH12013500107A1 (en) 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
BR112015000150A2 (pt) 2012-07-06 2017-06-27 Egalet Ltd composições farmacêuticas dissuasoras de abuso de liberação controlada
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
ES3008933T3 (en) 2015-09-29 2025-03-25 Merz Pharmaceuticals Llc Sustained release compositions of 4-aminopyridine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2223896A1 (de) † 1972-05-17 1973-11-29 Sanol Arznei Schwarz Gmbh Verfahren zum ueberziehen von feinteiligen arzneimitteln
DD146547A5 (de) † 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4377568A (en) † 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) † 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS5989622A (ja) † 1983-09-29 1984-05-23 Furointo Sangyo Kk 公害を生じないフイルムコ−テング法
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
EP0162492B1 (en) * 1984-04-11 1989-08-02 Thiemann Arzneimittel GmbH Dosage units for controlled release of active material
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4629619A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4663147A (en) * 1985-09-03 1987-05-05 International Minerals & Chemical Corp. Disc-like sustained release formulation
LU86099A1 (fr) * 1985-09-30 1987-04-02 Pharlyse Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
FI101344B1 (fi) † 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
US5254347A (en) † 1988-03-31 1993-10-19 Tanabe Seiyaku Co., Ltd. Controlled release pharmaceutical preparation and method for producing the same

Also Published As

Publication number Publication date
NO891052D0 (no) 1989-03-13
HU201882B (en) 1991-01-28
PT90153A (pt) 1989-11-10
DK156289A (da) 1989-10-01
ES2059729T3 (es) 1994-11-16
FR2629344A1 (fr) 1989-10-06
EP0335560A3 (en) 1990-12-27
PT90153B (pt) 1994-07-29
NO891052L (no) 1989-10-02
IL89695A0 (en) 1989-09-28
IE64348B1 (en) 1995-07-26
EP0335560B2 (en) 2002-01-23
KR950007202B1 (ko) 1995-07-04
EP0335560B1 (en) 1993-07-28
FI101344B (fi) 1998-06-15
DK156289D0 (da) 1989-03-30
CA1339078C (en) 1997-07-29
HK76195A (en) 1995-05-26
FI891163A0 (fi) 1989-03-10
IE891006L (en) 1989-09-30
HUT50050A (en) 1989-12-28
DE68907762T3 (de) 2003-11-20
PH25791A (es) 1991-11-05
FI101344B1 (fi) 1998-06-15
FI891163L (fi) 1989-10-01
AU610711B2 (en) 1991-05-23
ZA892131B (en) 1989-11-29
NO178136C (no) 1996-01-31
NO178136B (no) 1995-10-23
EP0335560A2 (en) 1989-10-04
AU3227389A (en) 1989-10-05
ATE91888T1 (de) 1993-08-15
DE68907762D1 (de) 1993-09-02
BG50712A3 (bg) 1992-10-15
KR890014095A (ko) 1989-10-21
DE68907762T2 (de) 1993-11-11
RU1836083C (ru) 1993-08-23
FR2629344B1 (fr) 1994-09-16
US5068112A (en) 1991-11-26

Similar Documents

Publication Publication Date Title
ES2059729T5 (es) Preparado farmaceutico de liberacion controlada y metodo para producir el mismo.
DK618088D0 (da) Farmaceutisk doseringsform til kontrolleret afgivelse af aktivt stof
NO851170L (no) Lagringsstabile, hurtignedbrytende farmasoeytiske virksomme stoff-presslegemer
NL300007I1 (nl) Preparaat voor de gereguleerde afgifte van een werkzame stof.
ES557836A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.
ATE151764T1 (de) Neue benzopyran-derivate, verfahren zu ihrer herstellung und ihre verwendung sowie die verbindungen enthaltenden zubereitungen
DE3685094D1 (de) Pharmazeutisches praeparat zur kontrollierten freisetzung von wirkstoffen.
IT8719064A0 (it) Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive.
NO871774L (no) Medikament-system med kontrollert frisettelse av det aktive middel.
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
DK0607118T3 (da) System til administrering af phospholipid
ES2060399T3 (es) Cristales de la hormona del crecimiento y procedimiento para la produccion de estos cristales de la hormona del crecimiento.
ES516375A0 (es) Procedimiento para la obtencion de una composicion a base de estireno para revestir alimentos y medicamentos.
NO871044L (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrimidinderivater.
FI872255A0 (fi) Menetelmä uusien, farmaseuttisesti aktiivisten 1-(hydroksistyryyli)-5H-2,3-bentsodiatsepiinijohdannaisten valmistamiseksi
NO893909D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazol-derivater.
ES2043696T3 (es) Derivados de prostaglandina e1 (derivados-pge1) como substancias activas farmaceuticas y medicamentos que contienen estos compuestos, especialmente para aplicacion transcutanea.
MX9301235A (es) DERIVADOS 1,4-DIOXINO(2,3-B)PIRIDINA. á
NO891114L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive arakidonsyre-derivater.
SE8102732L (sv) Biologiskt aktiva blandningar eller kompositioner samt salter av heterocykliska foreningar
IT8519296A0 (it) Derivati della idantoina, procedimento per la fabbricazione degli stessi e sostanza medicinale contenente i medesimi.
NO167802C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzotiazepinderivater.
IT7927443A0 (it) Metodo e dispositivo per la fabbricazione di corpi cavi cilindrici.
ES2054029T3 (es) Formulacion de acetato de flecainida con liberacion controlada.
AU6872487A (en) Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 335560

Country of ref document: ES